CompletedPhase 3

Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women

Canada238 participantsStarted 2011-10

Plain-language summary

The purpose of this Phase III trial is to evaluate the efficacy of oral administration of dehydroepiandrosterone (DHEA) combined with acolbifene (a selective estrogen receptor modulator (SERM)) on vasomotor symptoms (hot flushes) in postmenopausal women.

Who can participate

Age range40 Years – 75 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Main Inclusion Criteria: * Postmenopausal women (non-hysterectomized or hysterectomized). * Women between 40 and 75 years of age. * Willing to participate in the study and sign an informed consent. * Women having many moderate to severe hot flushes. * For non-hysterectomized women, willing to have an endometrial biopsy at baseline and end of-study. Main Exclusion Criteria: * Undiagnosed abnormal genital bleeding. * Hypertension equal to or above 140/90 mm Hg. * The administration of any investigational drug within 30 days of screening visit. * Endometrial hyperplasia (simple or complex hyperplasia with or without atypia), cancer or endometrial histology showing proliferative, secretory or menstrual type characteristics at histologic evaluation of endometrial biopsy performed at screening.

What they're measuring

Co-primary endpoint: change from baseline to week 12 in frequency of moderate to severe hot flushes.

Timeframe: 12 weeks

Co-primary endpoint: change from baseline to week 12 in severity of moderate to severe hot flushes.

Timeframe: 12 weeks

Trial details

NCT IDNCT01452373

SponsorEndoCeutics Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2012-12

View on ClinicalTrials.gov More Vasomotor Symptoms trials